Deleterious mutations in GATA3, an activating SF3B1 mutation (K700E), and an activating AKT1 mutation (E17K) were observed in eight (16.7%), three (6.3%), and three (6.3%) breast tumors, respectively. This evidence concerns the gene GATA3 and breast neoplasm.